Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for Adult ADHD with Anxiety and Depression
NCT01863459Phase 4Completed
- Sponsor
- Centre for Anxiety, Attention Deficit and Trauma
- Start
- Apr 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD), anxiety disorders and major depressive disorder (MDD) comparing Lisdexamfetamine Dimesylate with Placebo (2 arms). Primary endpoints: ADHD Rating Scale at 18 weeks and Clinical Global Impression - Improvement Scale at 18 weeks. Started Apr 2013; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)anxiety disordersmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01863459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863459.